Marina Tadolini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2876614/publications.pdf

Version: 2024-02-01

55 papers	2,402 citations	201385 27 h-index	214527 47 g-index
55 all docs	55 docs citations	55 times ranked	2546 citing authors

#	Article	IF	Citations
1	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	3.1	273
2	Tuberculosis elimination: theory and practice in Europe. European Respiratory Journal, 2014, 43, 1410-1420.	3.1	148
3	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, Januaryâ€“April 2020. Emerging Infectious Diseases, 2020, 26, 2709-2712.	2.0	133
4	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. European Respiratory Journal, 2016, 48, 1411-1419.	3.1	119
5	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. European Respiratory Journal, 2019, 54, 1901522.	3.1	113
6	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal, 2014, 44, 811-815.	3.1	96
7	On tuberculosis and COVID-19 co-infection. European Respiratory Journal, 2020, 56, 2002328.	3.1	93
8	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	3.1	92
9	First independent evaluation of QuantiFERON-TB Plus performance. European Respiratory Journal, 2016, 47, 1587-1590.	3.1	87
10	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. European Respiratory Journal, 2021, 58, 2101786.	3.1	86
11	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. European Respiratory Journal, 2016, 48, 935-938.	3.1	84
12	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office forÂEurope. European Respiratory Journal, 2019, 53, 1900391.	3.1	81
13	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal, 2016, 48, 938-943.	3.1	71
14	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. European Respiratory Journal, 2016, 47, 1758-1766.	3.1	69
15	Faster for less: the new â€œshorterâ€•regimen for multidrug-resistant tuberculosis. European Respiratory Journal, 2016, 48, 1503-1507.	3.1	66
16	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1300-1310.	2.5	61
17	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. European Respiratory Journal, 2018, 52, 1800934.	3.1	59
18	Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF. PLoS ONE, 2017, 12, e0176186.	1.1	55

#	Article	IF	Citations
19	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Journal of Thoracic Disease, 2017, 9, 2093-2101.	0.6	52
20	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences, 2017, 18, 341.	1.8	47
21	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	1.5	41
22	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	1.0	34
23	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	2.9	34
24	COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy. Infection, 2021, 49, 333-337.	2.3	33
25	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. European Respiratory Journal, 2014, 43, 286-289.	3.1	32
26	Compassionate and optimum use of new tuberculosis drugs. Lancet Infectious Diseases, The, 2015, 15, 1131-1132.	4.6	32
27	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. European Respiratory Journal, 2016, 48, 1527-1529.	3.1	28
28	Challenging MDR-TB clinical problems â€“ The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. International Journal of Infectious Diseases, 2019, 80, S68-S72.	1.5	21
29	Multidetector CT urography in urogenital tuberculosis: use of reformatted images for the assessment of the radiological findings. A pictorial essay. Abdominal Radiology, 2017, 42, 2314-2324.	1.0	20
30	Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. International Journal of Infectious Diseases, 2015, 32, 156-160.	1.5	19
31	Systematic Tuberculosis Screening in Asylum Seekers in Italy. Clinical Infectious Diseases, 2017, 65, 1407-1409.	2.9	18
32	Recommendations for treating children with drug-resistant tuberculosis. Pharmacological Research, 2016, 105, 176-182.	3.1	17
33	Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis. Medicine (United States), 2016, 95, e5347.	0.4	14
34	Silent oophoritis due to cytomegalovirus in a patient with advanced HIV disease. International Journal of STD and AIDS, 2000, 11, 410-412.	0.5	13
35	QuantiFERON-TB Performs Better in Children, Including Infants, than in Adults with Active Tuberculosis: a Multicenter Study. Journal of Clinical Microbiology, 2019, 57, .	1.8	13
36	Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider. European Respiratory Journal, 2014, 43, 678-684.	3.1	12

#	Article	IF	Citations
37	Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to antiâ€tubercular treatment. Transplant Infectious Disease, 2017, 19, e12658.	0.7	12
38	Trend of microbiologically-confirmed tuberculosis in a low-incidence setting with high immigration rates. BMC Public Health, 2014, 14, 340.	1.2	11
39	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. Paediatric Drugs, 2016, 18, 13-23.	1.3	11
40	Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 480-481.	4.6	10
41	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. Jornal Brasileiro De Pneumologia, 2022, 48, e20220087.	0.4	10
42	Do we need a new Fleming Ã©poque: The nightmare of drug-resistant tuberculosis. International Journal of Mycobacteriology, 2013, 2, 123-125.	0.3	9
43	How to manage children who have come into contact with patients affected by tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2015, 1, 1-12.	0.6	9
44	Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe. Travel Medicine and Infectious Disease, 2016, 14, 588-590.	1.5	9
45	Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Comparison with the pre-Haart period. Tuberculosis, 2003, 83, 319-328.	0.8	8
46	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. Journal of Thoracic Disease, 2015, 7, 1080-5.	0.6	8
47	Overview of fever of unknown origin in adult and paediatric patients. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 10-24.	0.4	8
48	Recommendations Concerning the Therapeutic Approach to Immunocompromised Children With Tuberculosis. Clinical Therapeutics, 2016, 38, 180-190.	1.1	7
49	Treatment of drug-susceptible and drug-resistant tuberculosis. , 0, , 152-178.		7
50	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. PLoS ONE, 2017, 12, e0189425.	1.1	6
51	Rituximab alone proves effective in the treatment of refractory, severe stage III AIDS-related non-Hodgkin's paediatric lymphoma. Aids, 2003, 17, 2146-2148.	1.0	5
52	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. BMJ Open, 2020, 10, e035350.	0.8	4
53	TB and MDR-TB: what is new in 2012?. Breathe, 2012, 9, 100-111.	0.6	2
54	The WHO strategy for TB control and elimination. , 2012, , 242-253.		0

#	Article	IF	Citations
55	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. Indian Journal of Medical Research, 2017, 145, 261-263.	0.4	0